Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.41 |
| ▸ | CES1 | P23141 | 2/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2657967 | 0.77 | CYP2D6 (0.34) | CES2CES1TRPA1CYP2D6SRC | |
| SCHEMBL857 | 0.76 | IDO1 (0.39) | CYP2D6SRCCYP1A2PKMSMN1; SMN2 | |
| SCHEMBL119992 | 0.73 | TSHR (0.44) | CES2CES1TRPA1CYP2D6SRC | |
| SCHEMBL16970628 | 0.73 | HCAR2 (0.43) | LMNAKMT2AALDH1A1 | |
| SCHEMBL3936005 | 0.73 | LMNA (0.43) | CES2CES1CYP2D6SRCCYP1A2 | |
| SCHEMBL7454768 | 0.73 | TSHR (0.44) | CES2CES1TRPA1CYP2D6SRC | |
| SCHEMBL96935 | 0.73 | HCAR2 (0.43) | LMNAKMT2AALDH1A1 | |
| SCHEMBL16970750 | 0.73 | HCAR2 (0.43) | LMNAKMT2AALDH1A1 | |
| SCHEMBL535087 | 0.73 | DPP4 (0.44) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| SCHEMBL2567616 | 0.72 | CYP2D6 (0.32) | CYP2D6SRCCYP1A2PKMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108147972-A | A kind of preparation method of Wei Patawei intermediates and the like | 成都西岭源药业有限公司 | 2018-06-12 | — | — | CN | claimed |
| CN-107810189-A | Method for preparing nitrogen mustard derivatives | 肿瘤多肽股份公司 | 2018-03-16 | — | — | CN | claimed |
| WO-2018022936-A1 | CLOSTRIDIUM DIFFICILE TARGETING MOIETIES AND CONSTRUCTS COMPRISING SAID MOIETIES | C3 JIAN, LLC (US) | 2018-02-01 | — | — | WO | claimed |
| CN-103827082-B | A kind of novel process preparing Peramivir and intermediate thereof | PHARMA RESOURCES (SHANGHAI) Co.,Ltd. (CN) | 2016-01-20 | — | — | CN | claimed |
| CN-103827082-A | A novel process for the preparation of peramivir and intermediates thereof | PHARMARESOURCES SHANGHAI CO LTD | 2014-05-28 | — | — | CN | claimed |
| EP-2485750-A1 | PEPTIDE-BASED PEROXIDASE INHIBITORS AND METHODS OF USING SAME | The MCW Research Foundation, Inc. (US) | 2012-08-15 | — | — | EP | claimed |
| CN-102443014-A | 3-chloro-cephalosporin derivative, synthetic method thereof and application thereof in preparation of cefaclor | SHANGHAI RIGHT HAND MEDICAL TECHNOLOGY DEV CO LTD | 2012-05-09 | — | — | CN | claimed |
| WO-2011044096-A1 | PEPTIDE-BASED PEROXIDASE INHIBITORS AND METHODS OF USING SAME | MCW RESEARCH FOUNDATION, INC. (US) | 2011-04-14 | — | — | WO | claimed |
| JP-2007512228-A | — | — | 2007-05-17 | — | — | JP | claimed |
| EP-1660112-A2 | ORALLY ADMINISTERED SMALL PEPTIDES SYNERGIZE STATIN ACTIVITY | The Regents of the University of California (US) | 2006-05-31 | — | — | EP | claimed |
| CN-1249024-C | Intermediate for synthesis of benzimidazole compound and process for producing the same | SANKYO CO (JP) | 2006-04-05 | — | — | CN | claimed |
| CN-1611489-A | Intermediates for the synthesis of benzimidazole compounds and process for preparation thereof | SANKYO CO (JP) | 2005-05-04 | — | — | CN | claimed |
| WO-2005016280-A2 | ORALLY ADMINISTERED SMALL PEPTIDES SYNERGIZE STATIN ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-02-24 | — | — | WO | claimed |
| WO-2003068806-A1 | SOLID PHASE PEPTIDE SYNTHESIS ON SILICA | JOHNSON MATTHEY PLC (GB) | 2003-08-21 | — | — | WO | claimed |
| CN-1371360-A | Intermediate for synthesis of benzimidazole compound and process for producing the same | SANKYO CO (JP) | 2002-09-25 | — | — | CN | claimed |
| EP-1000012-A1 | PROCESS FOR CONVERTING PROPARGYLIC AMINE-N-OXIDES TO ENAMINONES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-05-17 | — | — | EP | claimed |
| WO-1999006351-A1 | PROCESS FOR CONVERTING PROPARGYLIC AMINE-N-OXIDES TO ENAMINONES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-02-11 | — | — | WO | claimed |
| US-4269773-A | CEPHALOSPORINS | SHIONOGI & CO., LTD. (JP) | 1981-05-26 | — | — | US | claimed |
| US-20240207300-A1 | COMBINATION THERAPIES INCLUDING MYT1 INHIBITORS | SINAI HEALTH SYSTEM (CA) | 2024-06-27 | — | — | US | disclosed |
| US-4038222-A | OPIATE AGONIST | HOFFMAN-LA ROCHE INC. (US) | 1977-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207300-A1 | COMBINATION THERAPIES INCLUDING MYT1 INHIBITORS | WEE2, WEE1, KAT2A | CES2 2460/4885CES1 2420/4885TRPA1 4616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.